CRMD Insider Trading
CorMedix Inc. | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at CorMedix Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 05:30 | 2026-01-21 | Dillione Janet | Director | SELL | $6.88 | 10,000 | $68,800 | 38,473 | -20.6% |
| 2026-01-03 05:30 | 2025-12-30 | DUNTON ALAN W | Director | OPT+S | $13.00 | 20,000 | $260,000 | 40,250 | 0.0% |
| 2025-12-20 05:30 | 2025-12-18 | Todisco Joseph | Director, Officer - Chief Executive Officer | OPT+S | $12.00 | 30,000 | $360,000 | 509,496 | 0.0% |
| 2025-12-11 16:38 | 2025-12-09 | Dillione Janet | Director | OPT+S | $12.00 | 34,000 | $408,000 | 48,473 | 0.0% |
| 2025-12-11 05:38 | 2025-12-09 | Lefkowitz Steven W | Director | SELL | $11.88 | 40,000 | $475,200 | 80,498 | -33.2% |
| 2025-12-05 05:30 | 2025-12-02 | Dillione Janet | Director | OPT+S | $10.00 | 46,657 | $466,570 | 48,473 | 0.0% |
| 2025-11-27 05:30 | 2025-11-24 | Dillione Janet | Director | OPT+S | $9.93 | 26,343 | $261,586 | 48,473 | 0.0% |
| 2025-11-19 05:45 | 2025-11-14 | Dillione Janet | Director | SELL | $11.42 | 30,000 | $342,600 | 48,473 | -38.2% |
| 2025-10-28 04:30 | 2025-10-23 | Kaplan Myron | Director | BUY | $11.02 | 25,000 | $275,500 | 201,034 | +14.2% |
| 2025-09-17 04:45 | 2025-09-12 | DUNTON ALAN W | Director | OPT+S | $13.13 | 10,000 | $131,300 | 40,250 | 0.0% |
| 2025-09-13 04:45 | 2025-09-12 | Todisco Joseph | Officer - Chief Executive Officer | OPT+S | $13.00 | 50,000 | $650,000 | 509,496 | 0.0% |
| 2025-09-12 04:45 | 2025-09-09 | Zelnick Kaufman Beth | Officer - Chief Legal Officer | OPT+S | $13.41 | 50,000 | $670,265 | 180,418 | 0.0% |
| 2025-09-12 04:45 | 2025-09-09 | Hurlburt Elizabeth | Officer - Chief Operating Officer | OPT+S | $13.18 | 53,997 | $711,815 | 176,990 | 0.0% |
| 2024-12-14 00:15 | 2024-10-31 | Mistry Erin | Officer - EVP, Chief Commercial Officer | BUY | $9.99 | 1,500 | $14,985 | 52,011 | +3.0% |
| 2024-11-19 04:37 | 2024-11-14 | Hurlburt Elizabeth | Officer - EVP | OPT+S | $11.18 | 140,027 | $1,565,670 | 45,397 | 0.0% |
| 2024-03-14 15:45 | 2024-03-13 | Todisco Joseph | Director, Officer - Chief Executive Officer | BUY | $3.74 | 13,561 | $50,718 | 352,839 | +4.0% |
| 2023-12-19 00:47 | 2023-12-14 | DUNTON ALAN W | Director | BUY | $3.38 | 6,000 | $20,250 | 15,250 | +64.9% |
| 2023-11-22 00:00 | 2023-11-17 | Mistry Erin | Officer - Chief Commercial Officer | BUY | $4.00 | 1,000 | $4,000 | 4,900 | +25.6% |
| 2023-09-08 23:21 | 2023-09-08 | Todisco Joseph | Director, Officer - Chief Executive Officer | BUY | $3.71 | 10,000 | $37,100 | 219,726 | +4.8% |
| 2023-05-19 23:02 | 2023-05-18 | Kaplan Myron | Director | BUY | $4.54 | 6,000 | $27,258 | 166,034 | +3.7% |
| 2023-05-19 01:26 | 2023-05-17 | Costa Paulo F | Director | BUY | $4.65 | 10,000 | $46,500 | 10,000 | +100.0% |
| 2023-05-18 23:51 | 2023-05-17 | Stewart Robert A | Director | BUY | $4.37 | 10,000 | $43,735 | 11,000 | +1,000.0% |
| 2023-05-18 23:49 | 2023-05-17 | Todisco Joseph | Director, Officer - Chief Executive Officer | BUY | $4.58 | 5,000 | $22,900 | 209,726 | +2.4% |
| 2023-05-19 00:05 | 2023-05-17 | DUNTON ALAN W | Director | BUY | $4.33 | 3,000 | $12,980 | 9,250 | +48.0% |
| 2022-11-17 00:56 | 2022-11-15 | Todisco Joseph | Director, Officer - Chief Executive Officer | BUY | $3.82 | 20,000 | $76,400 | 242,169 | +9.0% |
| 2022-08-25 15:37 | 2022-08-24 | Todisco Joseph | Director, Officer - Chief Executive Officer | BUY | $3.92 | 4,700 | $18,424 | 222,169 | +2.2% |
| 2022-05-19 00:21 | 2022-05-17 | Kaplan Myron | Director | BUY | $3.78 | 5,000 | $18,900 | 160,034 | +3.2% |
| 2022-05-17 15:30 | 2022-05-16 | Todisco Joseph | Director, Officer - Chief Executive Officer | BUY | $3.38 | 10,000 | $33,800 | 217,469 | +4.8% |
| 2021-12-08 02:44 | 2021-12-06 | David Matthew T | Officer - Interim CEO and CFO | BUY | $4.50 | 1,000 | $4,500 | 3,150 | +46.5% |
| 2021-11-20 00:45 | 2021-11-16 | Kaplan Myron | Director | BUY | $5.14 | 10,000 | $51,400 | 175,034 | +6.1% |
| 2021-11-19 17:53 | 2021-11-17 | David Matthew T | Officer - Interim CEO and CFO | BUY | $5.07 | 1,000 | $5,070 | 2,150 | +87.0% |
| 2021-05-25 23:46 | 2021-05-21 | Masson-Hurlburt Elizabeth | Officer - EVP, Head of Clinical Ops | SELL | $6.92 | 8,000 | $55,394 | 0 | -100.0% |
| 2021-05-20 00:40 | 2021-05-17 | Kaplan Myron | Director | BUY | $6.03 | 15,000 | $90,477 | 165,034 | +10.0% |
| 2020-09-09 15:47 | 2020-09-04 | Lefkowitz Steven W | Director | BUY | $3.99 | 5,715 | $22,815 | 60,498 | +10.4% |
| 2020-09-08 15:38 | 2020-09-03 | David Matthew T | Officer - Chief Financial Officer | BUY | $4.07 | 1,150 | $4,681 | 1,150 | +100.0% |
| 2020-09-04 15:25 | 2020-09-02 | Kaplan Myron | Director | BUY | $4.27 | 15,300 | $65,359 | 150,034 | +11.4% |
| 2020-08-21 00:53 | 2020-08-18 | Khan Mehmood | Director | BUY | $4.84 | 45,750 | $221,352 | 178,767 | +34.4% |
| 2020-08-18 02:08 | 2020-08-13 | Mounts Phoebe | Officer - General Counsel | BUY | $4.03 | 2,525 | $10,176 | 7,200 | +54.0% |
| 2020-08-18 02:02 | 2020-08-13 | Kaplan Myron | Director | BUY | $4.08 | 15,000 | $61,160 | 134,734 | +12.5% |
| 2020-08-18 01:45 | 2020-08-13 | Baluch Khoso | Director, Officer - Chief Executive Officer | BUY | $4.14 | 4,830 | $19,985 | 60,905 | +8.6% |
| 2020-08-18 03:06 | 2020-08-14 | ARMSTRONG JR. JOHN L. | Officer - Exec VP of Tech Operations | BUY | $4.22 | 27,500 | $116,111 | 96,878 | +39.6% |
| 2020-08-15 00:29 | 2020-08-12 | DUNTON ALAN W | Director | BUY | $3.95 | 5,000 | $19,750 | 6,250 | +400.0% |
| 2020-05-18 23:20 | 2020-05-15 | Kaplan Myron | Director | BUY | $3.85 | 10,000 | $38,500 | 119,734 | +9.1% |
| 2020-03-19 23:18 | 2020-03-18 | Mounts Phoebe | Officer - General Counsel | BUY | $3.05 | 3,250 | $9,913 | 4,675 | +228.1% |
| 2020-03-18 23:25 | 2020-03-18 | Baluch Khoso | Director, Officer - Chief Executive Officer | BUY | $2.61 | 3,500 | $9,135 | 56,075 | +6.7% |
| 2020-01-03 01:24 | 2019-12-30 | Mounts Phoebe | Officer - General Counsel | BUY | $7.04 | 1,425 | $10,038 | 1,425 | +100.0% |
| 2019-12-18 01:09 | 2019-12-13 | Khan Mehmood | Director | BUY | $6.58 | 17,000 | $111,925 | 133,017 | +14.7% |
| 2019-10-02 00:14 | 2019-09-30 | Kaplan Myron | Director | BUY | $6.81 | 5,000 | $34,050 | 109,734 | +4.8% |
| 2019-10-02 00:19 | 2019-09-27 | Lefkowitz Steven W | Director | BUY | $6.75 | 5,000 | $33,750 | 55,276 | +9.9% |
| 2019-10-02 00:13 | 2019-09-30 | Cook Robert W. | Officer - Chief Financial Officer | BUY | $6.88 | 1,000 | $6,879 | 27,517 | +3.8% |
How to Interpret $CRMD Trades
Not every insider transaction in CorMedix Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CRMD shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for CRMD
Insider activity data for CorMedix Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CRMD, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.